- Home
- TOVX vs DBL Comparison
TOVX vs DBL Comparison
Compare TOVX & DBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TOVX | DBL |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 285.5M |
| IPO Year | 2012 | 2011 |
Fundamental Metrics
Financial Performance| Metric | TOVX | DBL |
|---|---|---|
| Price | $0.25 | $14.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 494.7K | 49.6K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.67% |
| EPS Growth | ★ 89.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $13.95 |
| 52 Week High | $0.86 | $15.79 |
Technical Indicators
Market Signals| Indicator | TOVX | DBL |
|---|---|---|
| Relative Strength Index (RSI) | 52.76 | 43.99 |
| Support Level | $0.22 | $13.95 |
| Resistance Level | $0.26 | $14.44 |
| Average True Range (ATR) | 0.01 | 0.11 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 43.83 | 20.00 |
Price Performance
Historical ComparisonAbout TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
About DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.